País: Canadà
Idioma: anglès
Font: Health Canada
DESLORATADINE
PHARMASCIENCE INC
R06AX27
DESLORATADINE
5MG
TABLET
DESLORATADINE 5MG
ORAL
10/20/30/50
OTC
SECOND GENERATION ANTIHISTAMINES
Active ingredient group (AIG) number: 0143961001; AHFS:
APPROVED
2009-11-06
_DESLORATADINE ALLERGY _CONTROL page 1 of 37 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION DESLORATADINE ALLERGY CONTROL Desloratadine Tablet, 5mg, Oral House Standard Histamine H1-Receptor Antagonist PHARMASCIENCE INC. 6111 Royalmount Avenue, Suite 100 Montréal, Canada H4P 2T4 Date of initial Authorization: SEP 22, 2011 Date of Revision: SEP 12, 2023 Submission Control Number: 272961 _DESLORATADINE ALLERGY _CONTROL page 2 of 37 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ................................................................................... 4 1 INDICATIONS .................................................................................................................................... 4 1.1 PEDIATRICS .................................................................................................................................... 4 1.2 GERIATRICS .................................................................................................................................... 4 2 CONTRAINDICATIONS ....................................................................................................................... 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX .................................................................................. 4 4 DOSAGE AND ADMINISTRATION ....................................................................................................... 4 4.1 DOSING CONSIDERATIONS ................................................................................................................ 4 4.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT ............................................................................. 5 4.3 ADMINISTRATION ............................................................................................................................ 5 4.4 MISSED DOSE ................................................................................................................................ 5 5 OVERDOSAGE ...................................... Llegiu el document complet